Altimmune, Inc. (NASDAQ: ALT) reported Q3 EPS of ($0.21), $0.06 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $5 thousand versus the consensus estimate of $2.14 thousand.

For earnings history and earnings-related data on Altimmune, Inc. (ALT) click here.